About
Overview
Leadership
Pipeline
Overview
ONCT-808
ONCT-534
Zilovertamab
Science
Overview
Publications
Investors
Overview
News Releases
Events & Presentations
Financial Reports
Stock Information
Analyst Coverage
Corporate Governance
Patients
Careers
Current Opportunities
Vision, Mission and Impact
Contact
Pyrazol-q-yl-Propanamides as Selective Androgen Receptor Degraders (SARDs) and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer. (He Y et al., J. Med. Chem. 2020 Nov 12. PMID: 33095584)
Please ensure Javascript is enabled for purposes of
website accessibility
About
Overview
Leadership
Pipeline
Overview
ONCT-808
ONCT-534
Zilovertamab
Science
Overview
Publications
Investors
Overview
News Releases
Events & Presentations
Financial Reports
Stock Information
Analyst Coverage
Corporate Governance
Patients
Careers
Current Opportunities
Vision, Mission and Impact
Contact